Managers / Q1 2022 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $680M in U.S.-listed holdings across 14 positions for Q1 2022.
Its largest position, Blueprint Medicines, represents 7.3% of the portfolio.
Compared with Q4 2021, the fund opened 1 new position and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 49.7% · $338M
- Common Stock · 41.5% · $282M
- Other · 6.9% · $47M
- ADR · 2.0% · $14M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| XBISPDR S&P BIOTECH ETF TR | NEW | +2.00M | 2.00M | +$180M | $180M |
| MAGENTA THERAPEUTICS INC | SOLD OUT | −3.16M | 0 | −$14M | $0 |
| SPYSPDR S&P 500 ETF TR | TRIMMED | −650.0K | 350.0K | −$317M | $158M |
| ARWRARROWHEAD PHARMACEUTICALS IN | ADDED | +347.0K | 1.05M | +$2M | $48M |
| MERUS N V | ADDED | +365.0K | 1.26M | +$5M | $33M |
| QUREUNIQURE NV | ADDED | +225.3K | 901.5K | +$2M | $16M |
| GMABGENMAB A/S | ADDED | +40.0K | 167.5K | +$1M | $6M |
| ARVNARVINAS INC | ADDED | +131.8K | 695.2K | +$508,000 | $47M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BLUEPRINT MEDICINES CORP | COM | 7.34% | $50M | 781.5K |
| 2 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 7.08% | $48M | 1.05M |
| 3 | ARVNARVINAS INChistory → | COM | 6.88% | $47M | 695.2K |
| 4 | SPROSPERO THERAPEUTICS INChistory → | COM | 6.75% | $46M | 5.28M |
| 5 | RGNXREGENXBIO INChistory → | COM | 5.46% | $37M | 1.12M |
| 6 | MERUS N V | COM | 4.90% | $33M | 1.26M |
| 7 | FDMT4D MOLECULAR THERAPEUTICS INhistory → | COM | 3.90% | $27M | 1.76M |
| 8 | QUREUNIQURE NVhistory → | SHS | 2.39% | $16M | 901.5K |
| 9 | AMRYT PHARMA PLC | SPONSORED ADS | 1.99% | $14M | 1.64M |
| 10 | PIERIS PHARMACEUTICALS INC | COM | 1.65% | $11M | 3.71M |
| 11 | ARGXARGENX SEhistory → | SPONSORED ADR | 1.11% | $8M | 24.0K |
| 12 | GMABGENMAB A/S | SPONSORED ADS | 0.89% | $6M | 167.5K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.